Member Info for HongKong

Isn’t this pretty important: 32% of patients were in remission considering a clinical response as a SLEDAI-2K Clinical score of 0‘ ?
This is a significant increase over the 7.6% of patients receiving Lupuzor in the one year Phase Three trial (vs zero in placebo plus SoC).
So, it works and it is safe.

Wonder if it was placed by someone at the AGM ??

Interesting. But perhaps a partner would rather agree to fund a clinical trial, in exchange for revenues, as opposed to writing a cheque to the corporate entity. That way they get pure exposure to Lupuzor and not to corporate risk ?

The timing appears to have been orchestrated for Lanstead to get set before the positive extension results RNS. Why else would they invest ?

I don’t think it is like that at all. I think it is less like an exam, as P3 was, and more like continuous assessment. They will have had access to data for 62 patients for over 12 months on a continuous basis. Perhaps this underlies their confidence that Lupuzor works and perhaps this is why they are confident in finding a partner, who may also have had access to this data after having signed a NDS

Why would the next Phase III cost £50m when the last one cost £13m ?

Yes. They will need a partner. Which is why the final results said ‘discussions continue with potential corporate partners’. I think TM mentioned one or two months in his Proactive interview. This should be seen as good news, non-dilutive financing at an implied valuation higher than the current stock price (else why not raise equity and keep 100% of the economics ?)

All these many years of research go some way toward explaining why the IMM team have all stayed at the company in spite of the disappointing Phase III result last year and subsequent collapse in share price (weighted average option exercise price is 79 pence, so all massively out of the money). They KNOW that this drug works. I imagine the extended trial has further reinforced this confidence; we shall find out in less than three weeks when those trail results are made public. Rather, it is the design of the Phase III trial itself, and the US cohort being atypical, that combined to give the disappointing trial result. This is what the next Phase III trial will seek to solve for, exactly as argued in Dr Malik’s research piece.

xxx should read penicillin, I had to double check it really was discovered by accident. It was. By Alexander Fleming in 1928. He was an immunologist. Funny coincidence, that

This is even better. A mini documentary. Highlights include
Discovered 17 years ago
60% do not receive appropriate treatment
Other treatments might be effective but they weaken the overall immune defence leaving the patient unprotected from infections.
Illustration of how lupus arises.
How Dr Muller came across Lupuzor pretty much by accident (xxx anyone) as she was trying to understand exactly how lupus arises. Her team found the exact peptide that can prevent lupus and exactly where it originates. P140 has been patented since 2001. After 34 years of research.
https://youtu.be/y7VG3KCRoS8

Found this on youtube, Dr Syviane Muller, talks about how she discovered Lupazor and why it is both efficacious and safe. Further, she talks about its possible use as a platform for treatment of other autoimmune diseases, even including asthma, which I didn’t even know was an autoimmune disease, but it is.
https://youtu.be/q15IjViIygc

Please address any enquiries to:
hello@thelifesciencesdivision.com

Happy to ask, but please be more specific as to the question

It is clear that Alaska is a ‘hot’ zone for exploration. See comments on ConocoPhillips, Repsol etc. And PANR is clear in saying that it’s goal is to explore, prove and then sell to a major. So I conclude that it will be enough to do exactly that. The majors have huge budgets and will take a long term view which will necessarily consider the optionality of higher than current oil prices, as they are doing today.

Did anyone attend the lunch this week ? I was out of town. Would love to hear what was said

As someone else had commented, the substitute products are imported and priced in US$. Given that Harvest prices its product with reference to the substitutes (US$) and that costs are in BRL then US$ margins and profits could even go up as the BRL depreciates against the US$. And, of course, £ is weak agains the US$ so £ profits could rise even more

Was out of town unfortunately

Is anyone going to the AGM on Monday ?

Does anyone have access to this article ? If so, please do kindly share, thanks

I attended. An excellent presentation from Mark. In the Q and A someone asked about customer experience. Mark said that one of the earliest customers was a coffee grower adjacent to the site. Two comments which I found interesting: 1. This customer took 20 tonnes first time around for a trial and then gave a second order for 120 tonnes. 2. The customer commented that the delivered all-in cost of KPF was less than the cost of transport/delivery of the product that he used to use. Pretty clear that the product is efficacious and very well priced.